-The Telegraph New Delhi: Regulatory efforts to get doctors in India to prescribe medicines only through their generic names, initiated about 15 years ago, will need to overcome legal challenges and resistance from sections of doctors and the pharmaceutical industry, experts said. Senior pharmacologists and industry analysts have also said it will be misleading to presume that prescriptions with generic names will automatically translate into lower medicine bills for patients as studies...

-Frontline Medecins Sans Frontieres warns that the free or regional trade agreements that are being negotiated, which seek to strengthen current patent regimes, are a potential threat to the developing world’s access to life-saving drugs, which it sources mostly from India. WHEN NELSON MANDELA’S GOVERNMENT passed the Medicines and Related Substances Control Act in 1997 to make medicines more accessible to the poor, 39 big pharmaceutical companies filed law suits in...

-The Times of India MUMBAI: For the first time ever, some of India's biggest pharmaceutical companies, cutting across their respective associations and representing nearly half the Rs 93,000 crore market, have come together to push for ethical marketing practices to clean up the industry's image. The forum, comprising of 40 to 50 domestic and MNC firms, had its first closed-door meeting on October 14. It has made a "voluntary and moral commitment"...

-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the...

-Business Standard This would be in addition to 348 drugs already under price ceiling The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of another 52 essential drugs, in a move that could impact drug manufacturers Lupin, Cadila Healthcare and Merck. This is in addition to the 348 drugs already under a price ceiling. The majority of the 52 new drugs are antibiotics, painkillers and medicines used for treating cancer and skin...